Sentences with phrase «share repurchase program in»

Not exact matches

In an open letter to Apple CEO Tim Cook, posted to Icahn's website Thursday, he outlined a share buyback program in which Apple would repurchase $ 150 billion of its own stock in order to improve company growtIn an open letter to Apple CEO Tim Cook, posted to Icahn's website Thursday, he outlined a share buyback program in which Apple would repurchase $ 150 billion of its own stock in order to improve company growtin which Apple would repurchase $ 150 billion of its own stock in order to improve company growtin order to improve company growth.

Jim Cramer highlights large share repurchase programs at Apple, Boeing and others in a market that's grown sour on buybacks.

Jim Cramer highlights share repurchase programs at Apple, Boeing and others in a market that's grown sour on buybacks.

Since 2012, when the company launched the largest share repurchase program ever, Apple has returned a little more than $ 100 billion to shareholders in stock buybacks and dividends.

Maestri said that since Apple has now completed $ 275 billion of its $ 300 billion capital return program, including $ 200 billion in share repurchases, Apple will complete its original plan three quarters early, in June.

«We are very pleased that MSG's board of directors and management have committed to pursue a plan to enhance value for all MSG shareholders through the combination of a share repurchase program and contemplated business spin - off... We look forward to the full and timely implementation of these plans,» JAT Capital Management LP said in an email to Reuters.

These risks and uncertainties include: Gilead's ability to achieve its anticipated full year 2018 financial results; Gilead's ability to sustain growth in revenues for its antiviral and other programs; the risk that private and public payers may be reluctant to provide, or continue to provide, coverage or reimbursement for new products, including Vosevi, Yescarta, Epclusa, Harvoni, Genvoya, Odefsey, Descovy, Biktarvy and Vemlidy ®; austerity measures in European countries that may increase the amount of discount required on Gilead's products; an increase in discounts, chargebacks and rebates due to ongoing contracts and future negotiations with commercial and government payers; a larger than anticipated shift in payer mix to more highly discounted payer segments and geographic regions and decreases in treatment duration; availability of funding for state AIDS Drug Assistance Programs (ADAPs); continued fluctuations in ADAP purchases driven by federal and state grant cycles which may not mirror patient demand and may cause fluctuations in Gilead's earnings; market share and price erosion caused by the introduction of generic versions of Viread and Truvada, an uncertain global macroeconomic environment; and potential amendments to the Affordable Care Act or other government action that could have the effect of lowering prices or reducing the number of insured patients; the possibility of unfavorable results from clinical trials involving investigational compounds; Gilead's ability to initiate clinical trials in its currently anticipated timeframes; the levels of inventory held by wholesalers and retailers which may cause fluctuations in Gilead's earnings; Kite's ability to develop and commercialize cell therapies utilizing the zinc finger nuclease technology platform and realize the benefits of the Sangamo partnership; Gilead's ability to submit new drug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (tprograms; the risk that private and public payers may be reluctant to provide, or continue to provide, coverage or reimbursement for new products, including Vosevi, Yescarta, Epclusa, Harvoni, Genvoya, Odefsey, Descovy, Biktarvy and Vemlidy ®; austerity measures in European countries that may increase the amount of discount required on Gilead's products; an increase in discounts, chargebacks and rebates due to ongoing contracts and future negotiations with commercial and government payers; a larger than anticipated shift in payer mix to more highly discounted payer segments and geographic regions and decreases in treatment duration; availability of funding for state AIDS Drug Assistance Programs (ADAPs); continued fluctuations in ADAP purchases driven by federal and state grant cycles which may not mirror patient demand and may cause fluctuations in Gilead's earnings; market share and price erosion caused by the introduction of generic versions of Viread and Truvada, an uncertain global macroeconomic environment; and potential amendments to the Affordable Care Act or other government action that could have the effect of lowering prices or reducing the number of insured patients; the possibility of unfavorable results from clinical trials involving investigational compounds; Gilead's ability to initiate clinical trials in its currently anticipated timeframes; the levels of inventory held by wholesalers and retailers which may cause fluctuations in Gilead's earnings; Kite's ability to develop and commercialize cell therapies utilizing the zinc finger nuclease technology platform and realize the benefits of the Sangamo partnership; Gilead's ability to submit new drug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (tPrograms (ADAPs); continued fluctuations in ADAP purchases driven by federal and state grant cycles which may not mirror patient demand and may cause fluctuations in Gilead's earnings; market share and price erosion caused by the introduction of generic versions of Viread and Truvada, an uncertain global macroeconomic environment; and potential amendments to the Affordable Care Act or other government action that could have the effect of lowering prices or reducing the number of insured patients; the possibility of unfavorable results from clinical trials involving investigational compounds; Gilead's ability to initiate clinical trials in its currently anticipated timeframes; the levels of inventory held by wholesalers and retailers which may cause fluctuations in Gilead's earnings; Kite's ability to develop and commercialize cell therapies utilizing the zinc finger nuclease technology platform and realize the benefits of the Sangamo partnership; Gilead's ability to submit new drug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (tprograms; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (the SEC).

On April 27, 2015, Apple announced that it had expanded its capital return program to $ 200 billion, which included an increase in its share repurchase authorization from $ 90 billion to $ 140 billion.

During the third quarter, NIKE, Inc. repurchased a total of 14.6 million shares for approximately $ 962 million as part of the four - year, $ 12 billion program approved by the Board of Directors in November 2015.

In its quarterly report on Tuesday, Apple said it would earmark $ 100 billion for a new share repurchase program, succeeding a $ 210 billion buyback program that started in 2012 and will wrap up this quarter - roughly nine months ahead of schedulIn its quarterly report on Tuesday, Apple said it would earmark $ 100 billion for a new share repurchase program, succeeding a $ 210 billion buyback program that started in 2012 and will wrap up this quarter - roughly nine months ahead of schedulin 2012 and will wrap up this quarter - roughly nine months ahead of schedule.

«In March 2012, the company announced a quarterly dividend and share repurchase program totaling $ 45 billion.

In addition, the company announced that its Board of Directors has authorized a share repurchase program under which the company may repurchase up to 3,500,000 shares of its outstanding common stock.

According to disclosures published by Grayscale in 2015, the program's repurchases took place at the same time that shares were being created by the trust — in violation of Regulation M.

If an Award expires or becomes unexercisable without having been exercised in full, is surrendered pursuant to an Exchange Program, or, with respect to Restricted Stock, Restricted Stock Units, Performance Units or Performance Shares, is forfeited to or repurchased by the Company due to failure to vest, the unpurchased Shares (or for Awards other than Options or Stock Appreciation Rights the forfeited or repurchased Shares), which were subject thereto will become available for future grant or sale under the Plan (unless the Plan has terminated).

The reduction in outstanding shares resulting from the stock repurchase program increased fiscal 2014 EPS.

For private stock, you have to dig a little deeper to find someone willing to buy the shares, or let the company repurchase the shares from you in stock buyback program.

When a board of directors authorizes a share repurchase program, it typically states either the number of shares the company is interested in buying back or a dollar amount it will spend on its stock buyback.

Add to that a share repurchase program that has reduced share count by over 3 % in the last year, and suddenly Apple looks a lot more lucrative to conservative investors.

In what could be called the «ultimate stock buyback program,» TPL is using multiple income streams to eventually repurchase all of its outstanding shares.

In the second quarter of 2014, the company repurchased 936,060 shares of its common stock under its share repurchase program for approximately $ 52 million.

Through July 22, 2014, the company has repurchased a total of nearly 2.5 million shares for a total of $ 134 million since the launch of the program in the fourth quarter of 2013.

In less than a year, we have repurchased $ 186 million of common stock under our share repurchase program, virtually exhausting the Board's original repurchase authorization.

There has been a lot of commentary around the historically high levels of share repurchases, and if its not the increase in stock - based compensation, what is the reason for the increase in buyback programs?

«On October 24, 2017, our board of directors authorized a $ 150.0 million stock repurchase program, allowing us to repurchase shares of our common stock over a two - year period from time to time at various prices in the open market or through private transactions.

``... We look forward to the capital return program update in April, anticipating it will include a large increase to share repurchases,» Icahn wrote.

In addition, its new management team announced a $ 50 million share - repurchase program that could add a lot of value for its shareholders if the company is cleared from any wrongdoing, or gets away with only paying small fines.

Another positive in the outlook: ON put its share repurchase program back in place.

The company halted its share repurchase program earlier this year when it saw weakness in the business, but has gotten more aggressive again with the stock at these levels, shrinking the shares substantially in only a couple months.

In addition, Apple has managed to pay out a regular, growing dividend while spending $ 173 billion repurchasing its own shares since initiating a capital - return program in 201In addition, Apple has managed to pay out a regular, growing dividend while spending $ 173 billion repurchasing its own shares since initiating a capital - return program in 201in 2012.

This press release contains forward - looking statements including those regarding the continued growth in the Company's business and the Company's ability to generate cash flows and maintain its cash dividend and / or share repurchase programs.

The Templeton closed - end Funds referenced above, which trade on the New York Stock Exchange, announced today that each Fund's Board has approved a modification to the Funds» existing open - market share repurchase programs to authorize each Fund to repurchase up to 10 % of a Fund's outstanding shares in open - market transactions, at the discretion of management.

The company first initiated a buyback program in 2012, authorizing $ 10 billion to be spent on share repurchases.

In Corning's 2014 annual statement they confirmed their commitment to returning cash to shareholders, citing their recent 20 % dividend increase and $ 1.5 billion share - repurchase program.

Lately we have seen several energy and materials companies raising their dividends, and in some cases they have reinstituted their share repurchase programs, which can be executed more effectively during periods of market weakness.

The company also has an active share repurchase program, having spent $ 1.4 billion to buy back 14 million shares in 2014 and another $ 211 million in the first two months of 2015 to buy back 1.9 million shares.

When a board of directors authorizes a share repurchase program, it typically states either the number of shares the company is interested in buying back or a dollar amount it will spend on its stock buyback.

In 2015, PM suspended its share repurchase program to ensure ample cash to cover current and future dividend payments.

Shares in Rich Uncles NNN REIT qualify for its Share Repurchase Program, as described in the Prospectus.

An active share repurchase program powered the large EPS increase — Valspar purchased 4.7 million of its shares in 2014.

In addition to the annual dividend, American States Water also has an active share repurchase program.

In October the share repurchase program was suspended to evaluate how best to allocate remaining cash [Ah... nice timing guys!].

In February 2009, our Board of Directors authorized a share repurchase program of up to $ 40 million of our common stock.

He advises a broad range of financial and corporate clients on the structuring, negotiation and execution of various equity - linked transactions, including public and private convertible debt and preferred stock issuances and associated derivative transactions, accelerated share repurchase programs, registered forward sale transactions, margin loan transactions in respect of large stakes in publicly traded companies, and equity - linked hedging and monetization transactions.

In 2017, we returned an aggregate of $ 325 million to stockholders through our share repurchase program and quarterly cash dividend.